In 2025 the US Food and Drug Administration took the most direct enforcement action it has taken against the compounded GLP-1 telehealth market. The agency announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products, with reporting describing the letters as threatening legal action without further notice.
These are not obscure regulatory filings. FDA warning letters are published on the agency’s website, searchable by company name, and written in plain language. Any patient can read the letter sent to a company they are considering buying from — and most patients have no idea they exist.
This article explains what the letters actually say, what a warning letter does and does not mean, and how to check whether a provider you are considering has received one. It is not a substitute for a conversation with your clinician about compounded GLP-1s. It is the piece of information that conversation should start from.
What a Warning Letter Actually Is
A Formal, Public Notice of Alleged Violation
A warning letter is the FDA telling a company in writing that it believes the company is violating federal law, and giving it an opportunity to correct the problem. It is published on the FDA website and remains publicly searchable.
Not the Same as a Recall or a Ban
A warning letter does not by itself remove a product from the market or prohibit a company from operating. It signals that the agency has identified a problem and expects it addressed — and that further action may follow if it is not.
Not a Finding That a Product Harmed Anyone
The 2025 letters largely concern false or misleading marketing claims and misbranding rather than documented patient harm. That is a meaningful distinction, and it cuts both ways: no harm finding, but also a formal statement that the company’s representations were not acceptable.
It Is Public, Which Is the Point
The FDA publishes warning letters precisely so that patients, prescribers and the industry can see them. A company that has received one cannot honestly describe it as a private regulatory matter.
It Is Legitimate Information for Your Decision
You are being asked to inject a prescription product weekly. Whether the company selling it has been formally told by the FDA that its products are misbranded is relevant information, and you are entitled to weigh it.
What the Letters Say
The FDA announced in 2025 that it had issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products. Reporting on the action described the agency threatening legal action without further notice, and characterised it as the FDA ramping up its crackdown on GLP-1 drug compounders.
One published example makes the language concrete. In the warning letter issued to LumiMeds on September 9, 2025, published as MARCS-CMS 716510, the agency stated that for the reasons discussed in the letter, the company’s compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act.
A separate letter issued the same day to a company operating as GLP-1 Solution shows the action was coordinated rather than isolated. The FDA has also published broader guidance setting out its concerns with unapproved GLP-1 drugs used for weight loss.
Misbranding Under Section 502(a)
Broadly, this concerns labelling that is false or misleading in any particular. In the GLP-1 telehealth context, the agency’s concerns have centred on marketing claims made about compounded products.
Misbranding Under Section 502(bb)
This provision relates to compounded drugs that do not meet the statutory conditions required to be exempt from certain requirements. It is the provision that becomes most relevant once a drug leaves the FDA shortage list.
Why the Shortage List Matters
While semaglutide and tirzepatide were on the FDA shortage list, compounding them occupied clearer legal ground. Both have since left that list, which narrowed the basis on which they can be compounded — and is the backdrop to the enforcement wave.
How to Check Whether Your Provider Received One
This takes about two minutes and is the single most useful piece of diligence available to a prospective patient of a compounded GLP-1 provider.
1. Search the FDA Warning Letter Database
The FDA publishes warning letters at fda.gov under Inspections, Compliance, Enforcement and Criminal Investigations. Search the company name. Letters are listed with a MARCS-CMS reference number and a date.
2. Search the Company Name Plus “FDA Warning Letter”
A plain web search for the provider name alongside the phrase will usually surface the letter directly, along with any trade press coverage of the enforcement action.
3. Read the Letter Itself, Not Coverage of It
FDA warning letters are short and written in accessible language. The letter tells you exactly what the agency objected to, which is more useful than a headline summarising it.
4. Ask the Company Directly
If a provider has received a warning letter, ask what they did in response. A company that has genuinely addressed the FDA’s concerns should be able to say what changed. A company that will not discuss it has answered a different question.
5. Check the Compounding Pharmacy Too
The telehealth company and the pharmacy that actually compounds your medication are usually different businesses. Ask which pharmacy dispenses your prescription, then check that name as well — the FDA also publishes a list of registered 503B outsourcing facilities.
What This Does Not Mean
It is worth being precise here, because both overstating and understating this matters.
A warning letter is not a finding that a company’s medication harmed patients. It is not a recall. It does not automatically mean a company is operating illegally today, since companies do respond to warning letters and correct the conduct at issue.
Equally, it is not a technicality, and it is not something a company can reasonably describe as routine. Thirty letters issued in a coordinated action, with reporting describing threats of legal action without further notice, is the FDA saying something specific and deliberate about how this market has been marketing itself.
The honest framing is this: a warning letter is a material fact about a company that you should know before buying from it, weighed alongside everything else you know. It is a reason to ask more questions, and for many patients a reason to choose a provider without one.
The Broader Regulatory Picture
The warning letters did not arrive in isolation. The compounded GLP-1 market grew during a period when semaglutide and tirzepatide were on the FDA drug shortage list, which created clearer legal space for pharmacies to compound them. Both molecules have since left that list, narrowing that space considerably.
Alongside the FDA action, manufacturers have pursued their own litigation, with Novo Nordisk suing telehealth companies over compounded semaglutide marketing. The FDA has separately published guidance on its concerns with unapproved GLP-1 drugs used for weight loss, and has noted that pharmacies are no longer permitted to regularly compound tirzepatide injections except in limited circumstances involving medical need.
For patients, the practical consequence is that the compounded GLP-1 market in 2026 sits on materially less certain ground than it did in 2023 or 2024. That does not make every compounded provider illegitimate. It does mean the questions worth asking — which pharmacy, what licensure, on what basis — carry more weight than they used to.
What to Do With This
Spend two minutes searching the FDA warning letter database for any compounded GLP-1 provider you are considering. It is free, it is public, and it is the highest-value diligence available to you. If a letter exists, read it before you read the pricing page.
If a provider you are considering has received a letter, that is not automatically disqualifying — but it does change what you should ask. What did the company do in response? Which pharmacy compounds your medication, and has it been the subject of any action? On what basis is the medication being compounded now that both molecules have left the shortage list?
We have reflected this in our own reviews. LumiMeds publishes some of the lowest compounded GLP-1 prices anywhere and has a genuinely well-designed pricing structure — and it received an FDA warning letter on September 9, 2025 stating its compounded semaglutide and tirzepatide products are misbranded drugs. Both facts belong in the same paragraph, which is why we put them there.
If you would rather avoid the question entirely, the brand-name manufacturer channels are the alternative. LillyDirect and NovoCare Pharmacy both publish self-pay pricing for FDA-approved products, and an insurance-first provider such as Measured may cost you less than either if your plan has a GLP-1 benefit.
Frequently Asked Questions
How many warning letters did the FDA issue?
The FDA announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1s. Reporting described the letters as threatening legal action without further notice. Separate reporting has referenced a batch of 25 letters, reflecting how the action was reported at different stages.
Which companies received warning letters?
The letters are published individually on the FDA website and are searchable by company name. One documented example is LumiMeds, which received a letter dated September 9, 2025 published as MARCS-CMS 716510. A company operating as GLP-1 Solution received a letter the same day. Search the FDA database for any specific provider you are considering.
Does a warning letter mean a company is illegal?
No. A warning letter is a formal notice that the FDA believes a company is violating federal law and expects the problem corrected. It is not a recall, a ban, or a court finding. Companies do respond and correct the conduct at issue. It is a material fact to weigh, not a verdict.
Does it mean the medication is dangerous?
The 2025 letters largely concern false or misleading marketing claims and misbranding rather than documented patient harm. That said, compounded preparations are not FDA-approved and have not been reviewed by the agency for safety, efficacy or manufacturing quality regardless of any warning letter. Discuss compounded GLP-1s with your own clinician.
How do I check whether my provider received one?
Search the FDA warning letter database at fda.gov under Inspections, Compliance, Enforcement and Criminal Investigations, using the company name. A plain web search combining the provider name with the phrase FDA warning letter will also usually surface it. It takes about two minutes.
Why did the FDA act now?
The compounded GLP-1 market grew substantially while semaglutide and tirzepatide were on the FDA drug shortage list, which created clearer legal space for compounding them. Both molecules have since left that list, narrowing that basis. The enforcement action followed, alongside manufacturer litigation and separate FDA guidance on unapproved GLP-1 drugs used for weight loss.
Can I still get compounded GLP-1s?
Compounded GLP-1s remain widely available. The regulatory position is narrower than it was: the FDA has noted that pharmacies are no longer permitted to regularly compound tirzepatide injections except in limited circumstances involving medical need. Ask any provider on what basis your specific medication is being compounded.
Should I switch providers if mine received a letter?
That is your decision to make with the full picture. Ask the company what it did in response, ask which pharmacy compounds your medication, and weigh the answer against what you would give up by switching. For many patients a comparably priced provider without a warning letter is the simpler choice.
Disclosure:
This article is based on publicly available FDA communications including published warning letters, the agency’s press announcement regarding warning letters issued to telehealth companies over compounded GLP-1 marketing, and its published guidance on unapproved GLP-1 drugs used for weight loss, together with trade press coverage of the enforcement action, current as of August 2026. Specific letters cited, including the letter to LumiMeds dated September 9, 2025 published as MARCS-CMS 716510, are public documents readers can verify directly on the FDA website. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. This is a plain-language summary and is not legal advice; the regulation of pharmacy compounding is complex and continues to develop through regulatory action and litigation. Nothing here is medical advice. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
The FDA Wants to End Compounded GLP-1s Permanently
The April 2026 proposal to exclude these molecules from the 503B bulks list.
Compounded GLP-1s After the Shortage Ended
What changed when semaglutide and tirzepatide left the FDA shortage list.
503A vs 503B Compounding Pharmacies
How FDA oversight differs between the two categories, and how to verify a licence.
LumiMeds Review
Low prices weighed against the September 2025 FDA warning letter.
How to Vet a GLP-1 Provider
Red flags, green flags and the questions to ask before you pay.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →